Literature DB >> 2335381

Tumour-bearing animals synthesize a decreased level of mRNA for the inducible 55,000 MW interleukin-2 receptor.

V Holán1, M Lipoldová.   

Abstract

Spleen cells from mice bearing progressive growing methylcholanthrene-induced syngenic tumours were deeply hyporeactive in response to T-cell mitogens. This hyporeactivity was associated with decreased ability to synthesize mRNA for the inducible 55,000 MW interleukin-2 receptor (IL-2R). Since the expression of functional IL-2R represents one of the early and pivotal events in lymphoid-cell activation, it is suggested that the defect in effective IL-2R expression may be one of the primary factors responsible for the immunological hyporeactivity of tumour-bearing hosts.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2335381      PMCID: PMC1385640     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  13 in total

Review 1.  The interleukin-2 receptor, its physiology and a new approach to a selective immunosuppressive therapy by anti-interleukin-2 receptor monoclonal antibodies.

Authors:  T Diamantstein; H Osawa
Journal:  Immunol Rev       Date:  1986-08       Impact factor: 12.988

Review 2.  Down-regulation of the antitumor immune response.

Authors:  R J North
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

3.  In vitro studies on mechanism of the "eclipse" of cell-mediated immunity in mice bearing advanced tumors.

Authors:  J K Youn; D Le François; G Barski
Journal:  J Natl Cancer Inst       Date:  1973-04       Impact factor: 13.506

Review 4.  The interleukin 2 receptor.

Authors:  K A Smith
Journal:  Adv Immunol       Date:  1988       Impact factor: 3.543

5.  Solubilized tumour-associated antigens of methyl-cholanthrene-induced mouse sarcomas. Comparative studies by in vitro sensitization of lymph-node cells, macrophage electrophoretic mobility assay and transplantation tests.

Authors:  J Bubeník; M Indrová; S Nemecková; M Malkovský; B Von Broen; V Pálek; J Anderlíková
Journal:  Int J Cancer       Date:  1978-03-15       Impact factor: 7.396

6.  Analysis of T-cell receptor usage in activated T-cell clones from Hashimoto's thyroiditis and Graves' disease.

Authors:  M Lipoldova; M Londei; B Grubeck-Loebenstein; M Feldmann; M J Owen
Journal:  J Autoimmun       Date:  1989-02       Impact factor: 7.094

7.  Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).

Authors:  K Itoh; K Shiiba; Y Shimizu; R Suzuki; K Kumagai
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

8.  Defect in lectin-induced interleukin 2 production by peripheral blood lymphocytes of patients with invasive urinary bladder carcinoma.

Authors:  J Bubeník; J Kieler; V Tromholt; G Hermann; T Jandlová
Journal:  Immunol Lett       Date:  1988-06       Impact factor: 3.685

9.  Establishment and characterization of a permanent T-cell line producing an antigen non-specific suppressor factor.

Authors:  V Holán; M Lipoldová; M Takác; J Cerná; A Vancatová; D Cechová; L Veselský; M Hasek
Journal:  Immunology       Date:  1985-10       Impact factor: 7.397

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.